Decision Counseling and Follow-up for Shield+ Patients
← catalyst calendarNCT07620535 · readout ≤ 499 d
Sponsored by Guardant Health, Inc. (industry) · GH — their whole pipeline →. With Thomas Jefferson University.
Phase
—
Status
Not yet recruiting
Study type
Observational
Enrollment
350estimated
Sites
1
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | Jun 2026 | estimated | When the study began enrolling |
| Primary completion | Dec 2027 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Jun 2028 | estimated | The whole study's end, after follow-up |
| First posted | 2026-06-02 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-06-02 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Colo-rectal Cancer
Intervention
- Behavioral: Decision Counseling Session
Primary outcomes
what the primary-completion date above is the date OFCDE Decisional Conflict
measured From Enrollment to the end of study at 6 months
Factors for CDE Decisional Conflict
measured From Enrollment to End of Study at 6 months
Factors for Changes in CDE Decisional Conflict
measured From Enrollment to End of Study at 6 months
Permalink · GH's whole pipeline · Catalyst calendar · Every registered study · What changed